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Abstract
 
A characteristic feature of systemic lupus erythematosus is the accumulation of activated/memory
T and B cells. These G
 
0
 
/G
 
1
 
-arrested cells express high levels of cyclin-dependent kinase inhibitors
such as p21, are resistant to proliferation and apoptosis, and produce large amounts of proinflam-
matory cytokines. Herein, we show that ablation of p21 in lupus-prone mice allows these cells to
reenter the cell cycle and undergo apoptosis, leading to autoimmune disease reduction. Absence
of p21 resulted in enhanced Fas/FasL-mediated activation-induced T cell death, increased activation
of procaspases 8 and 3, and loss of mitochondrial transmembrane potential. Increased apoptosis
was also associated with p53 up-regulation and a modest shift in the ratio of Bax/Bcl-2 toward
 
the proapoptotic Bax. Proliferation and apoptosis of B cells were also increased in p21
 
   
 
 lupus
mice. Thus, modulation of the cell cycle pathway may be a novel approach to reduce apoptosis-
resistant pathogenic lymphocytes and to ameliorate systemic autoimmunity.
Key words: CDKI • lupus • replicative senescence • Fas/FasL • cell cycle
 
Introduction
 
Foreign antigen-directed immune responses typically involve
a sequence of T and B cell activation, clonal expansion, dif-
ferentiation into effector cells, and, to maintain homeostasis,
apoptosis (1, 2). The fraction (
 
 
 
5%) that escapes apoptosis
constitutes the self-renewing, long-lived memory population.
Autoimmune responses are not as clearly defined in this
regard, although similar principles seem to govern antigen
presentation, costimulation, and cytokine requirements (3).
However, differences in the kinetics and homeostatic
mechanisms must exist because self-antigens are continually
present, and alterations in lymphocyte functions and pheno-
types are observed with autoimmune disease progression.
A common feature of lupus-prone mice is the marked
accumulation of activated/memory phenotype (CD44
 
hi
 
)
CD4
 
 
 
 T cells resistant to proliferation and apoptosis (4, 5).
Notably, such cells are arrested in the G
 
0
 
/G
 
1
 
-phase of the
cell cycle and express high levels of certain cyclin-dependent
kinase inhibitors (CDKIs), including p21
 
WAF-1/CIP-1
 
 (5),
characteristics that are also associated with replicative se-
nescence (6–8). We hypothesized (5) that repeated stimulation
of self-reactive T cells might lead to a state akin to “replicative
senescence,” wherein T cells no longer cycle, but persist
and transcribe autoimmunity-promoting genes such as those
encoding proinflammatory cytokines (9). A similar accumu-
lation of activated B cells resistant to proliferation and apop-
tosis is also found in lupus-prone strains (10–13).
Although cell cycle and apoptosis are opposing biologic
phenomena, studies have shown that they are interconnected
(14, 15). TCR-, mitogen-, and superantigen-mediated
apoptosis of mature T cells requires an initial progression
through several cellular divisions (16–18). Furthermore,
blocking cyclin B with antisense (AS) oligonucleotides inhibits
TCR signal–mediated apoptosis (19). Thus, cell cycle block-
ade at the G
 
0
 
/G
 
1
 
-phase could be a major factor in apoptosis
resistance and accumulation of activated/memory phenotype
T cells in systemic autoimmunity.
Cell cycle progression is controlled by several proteins,
including cyclins, cyclin-dependent kinases (CDKs), and
CDKIs (15, 20). CDKIs are negative regulators of cyclin–
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CDK complexes and, based on structural and functional
characteristics, have been grouped into two distinct fami-
lies, Ink4 and Cip/Kip (20, 21). The Ink4 proteins
(p16
 
INK4A
 
, p15
 
INK4B
 
, p18
 
INK4C
 
, and p19
 
INK4D
 
) form binary
complexes with CDK4 and CDK6 and block the G
 
1
 
 to S
phase transition. In contrast, the pancyclin Cip/Kip pro-
teins (p21
 
CIP-1
 
, p27
 
KIP1
 
, and p57
 
KIP2
 
) bind to the entire cy-
clin/CDK holoenzymes, inhibiting transitions at all stages
of the cell cycle. Among the CDKIs, p21 is likely to play a
prominent role in both cell cycle and apoptosis by promot-
ing G
 
1
 
-arrest, inhibiting proliferating cell nuclear antigen,
affecting key players in the apoptotic machinery (such as
p53 and procaspase 3), and contributing to cellular senes-
cence (21–24). The induction of p21 by several growth fac-
tors and cytokines, including IFN-
 
 
 
, has also been reported
(25, 26). Surprisingly, despite the multiple roles ascribed to
this CDKI and the wide range of cells expressing this gene
during development and cellular activation (21), p21-deleted
mice develop normally at least up to 7 mo of age (27).
In light of this, we reasoned that absence of p21 might
release repeatedly activated, self-reactive T and B cells from
their replication/apoptosis-resistant state, allowing their en-
try into the S phase and subsequent apoptosis, thus reduc-
ing their accumulation and presumptive pathogenicity in
systemic autoimmunity. Herein, we report that homozy-
gous deletion of the 
 
p21
 
 gene indeed reduced serologic,
cellular, and histologic disease manifestations and increased
survival of male BXSB lupus-prone mice. This resistance to
autoimmunity appeared to be primarily due to an increased
susceptibility of activated/memory phenotype T and B
cells to activation-induced cell death (AICD).
 
Materials and Methods
 
Mice.
 
p21
 
 
 
/
 
 
 
 mice, obtained from P. Leder (Harvard Medi-
cal School, Boston, MA), were backcrossed to the BXSB strain.
Only male p21
 
 
 
/
 
 
 
 and p21
 
 
 
/
 
 
 
 littermates were compared with
survival, serologic, and histopathologic data compiled from mice
at generations 7–11, and in vitro data from generations 10–13.
 
Flow Cytometry.
 
Cells were stained with antibodies to CD4,
CD5, CD8, CD11b, CD19, B220, CD21, CD23, CD25, CD27,
CD44, CD69, IgM, IgD, Annexin V, Fas, FasL, TCR
 
 
 
/
 
 
 
, IFN-
 
 
 
,
or PI (all obtained from BD Biosciences). Data were acquired on
a FACS Calibur™ and analyzed with CELLQuest™ software
(Becton Dickinson).
 
Proliferation and Apoptosis Assays.
 
In vitro studies were con-
ducted with cells from 1–2-mo-old mice, an age at which fre-
quencies and phenotypes of T and B cell subsets were equivalent
between the two genotypes. LN cells were incubated with 5 
 
 
 
g/
ml of soluble anti-CD28 and increasing concentrations of plate-
bound anti-CD3 (BD Biosciences) for 48 h. [
 
3
 
H]thymidine (1
 
 
 
Ci) incorporation was measured 15 h later. Subsequently, the
optimum coating concentration was selected (10 
 
 
 
g/ml of anti-
CD3), and LN cells were plated on anti-CD3–coated plates plus
5 
 
 
 
g/ml of soluble anti-CD28, and analyzed for [
 
3
 
H]thymidine
incorporation every 24 h for 6 d (28). B cells were activated with
10 
 
 
 
g/ml of soluble goat F(ab
 
 
 
)
 
2
 
 anti–mouse IgM (Jackson Im-
munoResearch Laboratories) and IL-4. [
 
3
 
H]Thymidine incorpo-
ration was measured every 24 h for 3 d. In vivo proliferation of
splenic T and B cells was determined by long-term bromode-
oxyuridine (BrdU) incorporation (29). In brief, BrdU was ad-
ministered in drinking water for 9 d (0.8 mg/ml), made fresh
daily. After BrdU labeling, splenocytes were analyzed by FACS
 
®
 
using the BrdU Flow kit (BD Biosciences) according to the man-
ufacturer’s instructions.
To assess T cell AICD, LN cells were cultured for 48 h with
0.5 
 
 
 
g/ml of soluble anti-CD3 and religated with 10 
 
 
 
g/ml of
plate-bound anti-CD3 (BD Biosciences; reference 18). To block
AICD, anti-FasL antibody (BD Biosciences) or soluble Fas/Fc (a
gift from D. Green, La Jolla Institute for Allergy and Immunol-
ogy, San Diego, CA) was added at 10 
 
 
 
g/ml, whereas anti-Fas
antibody (BD Biosciences) was added at 5 
 
 
 
g/ml to induce
AICD. For B cell apoptosis, splenocytes were incubated with 10
 
 
 
g/ml of soluble goat F(ab
 
 
 
)
 
2
 
 anti–mouse IgM.
T and B cells undergoing apoptosis were stained at 24-h inter-
vals with either anti-CD4, anti-CD8, or anti-CD19, plus Annexin
V and PI. The percentage of Annexin V
 
 
 
/PI
 
 
 
 T or B cells was de-
termined by FACS
 
®
 
. Loss of mitochondrial transmembrane poten-
tial was determined using the JC-1 mitochondrial transmembrane
potential (
 
  
 
m) detection kit (Cell Technology, Inc.) according
to the manufacturer’s instructions. Conversion of procaspases 8
and 3 to active caspases was assessed by the APO LOGIX carboxy-
fluorescein caspase detection kit and APO ACTIVE 3 antibody
detection kit (Cell Technology, Inc.), respectively.
 
RNase Protection Assay.
 
RNase protection assay of p21 ex-
pression on sorted CD19
 
 
 
 B cells was performed as described
previously (5). In brief, riboprobes for p21 and L32 (housekeep-
ing gene) were prepared and labeled with 
 
 
 
-[
 
32
 
P]UTP (Ribo-
probe System; Promega). Purified probes were hybridized to 5
 
 
 
g of total B cell RNA (RPA Kit I; Torrey Pines Biolabs), pro-
tected products were run on a 6% polyacrylamide sequencing gel,
and bands were revealed by overnight exposure on autoradio-
graphic film (Eastman Kodak Co.).
 
Stem and T Cell Cycling.
 
Bone marrow cells from 1-mo-old
and LN T cells from 3-mo-old male BXSB p21
 
 
 
/
 
 
 
 or p21
 
 
 
/
 
 
 
mice (
 
n 
 
  
 
4 mice/group) were stained with either a mouse lin-
eage panel and anti–Sca-1 (both obtained from BD Biosciences),
or anti-CD4 and anti-CD44. Cells were analyzed by FACS
 
®
 
 after
surface immunophenotyping and sequential incubation with 1.67
 
 
 
M of DNA-binding dye Hoechst 33342 (Molecular Probes)
and 1 
 
 
 
g/ml of RNA-binding dye Pyronin Y (Sigma-Aldrich;
reference 30).
 
AS Assays.
 
LN cells from 2-mo-old wild-type BXSB male
mice were activated with plate-bound anti-CD3 or religated to
induce apoptosis, as aforementioned, in the presence of 400 nM
of either of two Penetratin-1–coupled p21-specific phospho-
rothioated AS oligonucleotides: p21AS no. 1, 5
 
 
 
-ACATCAC-
CAGGATTGGACAT-3
 
 
 
 (31); and p21AS no. 2, 5
 
 
 
-TGTCAG-
GCTGGTCTGCCTCC-3
 
 
 
 (32) or a similarly processed control
oligonucleotide obtained from Qbiogene: control AS, 5
 
 
 
-TG-
GATCCGACATGTCAGA-3
 
 
 
 (32).
 
Western Blots.
 
Wild-type and p21
 
 
 
/
 
 
 
 BXSB T cells were ac-
tivated with 10 
 
 
 
g/ml anti-CD3 plus 5 
 
 
 
g/ml anti-CD28 and
analyzed for p21, Bax, Bcl-2, and p53 protein expression. In
brief, lysates were prepared from 2.0 
 
 
 
 10
 
7
 
 cells, and protein was
measured by microprotein assay (Bio-Rad Laboratories). Proteins
were separated on a 15% SDS-PAGE (Bio-Rad Laboratories),
transferred to polyvinyl difluoride membrane (Immobilon-P;
Millipore), and blocked with 5% milk powder in PBS. After
overnight incubation at 4
 
 
 
C with primary antibodies to p21, Bax,
Bcl-2, or p53, proteins were revealed with appropriate horserad-
ish peroxidase–conjugated secondary antibodies (BD Biosciences
or Santa Cruz Biotechnology, Inc.) followed by SuperSignal 
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chemiluminescence (Pierce Chemical Co.). Radiographs were
scanned on the Personal Densitometer SI and analyzed by Im-
ageQuant 4.2a (both Amersham Biosciences).
 
T-dependent (TD) Responses.
 
Mice were injected s.c. with
100 
 
 
 
g trinitrophenyl (TNP)–keyhole limpet hemocyanin
(KLH; Biosearch Technologies) emulsified in CFA. Secondary
responses were assessed by a s.c. boost of 100 
 
 
 
g TNP-KLH in
saline on day 21. Mice were bled at the indicated times, and anti-
body levels were determined by ELISA (33).
 
Serologic Analysis.
 
Total and antichromatin serum IgG sub-
classes were measured by ELISA using 96-well plates coated with
goat anti–mouse IgG (Jackson ImmunoResearch Laboratories) or
mouse chromatin (29). Bound IgG subclasses were detected using
AP-conjugated IgG subclass-specific antibodies (Caltag). Standard
curves for each subclass were generated using calibrated mouse
serum (Accurate Chemical and Scientific Company).
 
Kidney Disease.
 
AZOSTIX strips (Bayer) were used to mea-
sure blood urea nitrogen and graded on a 1–4 scale (1 
 
  
 
5–15,
2 
 
  
 
15–26, 3 
 
 
 
30–40, and 4 
 
  
 
50–90 mg/dl). Histologic exam-
ination of periodic-acid Schiff–stained kidneys was done in a
blind manner at 4 mo of age, and severity of glomerulonephritis
(GN) was defined on a scale of 0–4 (34). For immunohistology,
frozen kidney sections were fixed in ice-cold acetone, blocked,
and incubated with anti–IgG-FITC (Vector Laboratories); depos-
its were scored as described previously (29).
 
Statistics.
 
The Student’s 
 
t
 
 test was used for group mean com-
parisons, and survival was analyzed by the Kaplan-Meier method
with comparisons by log-rank test. P-values 
 
 
 
0.05 were consid-
ered significant.
 
Results
 
To examine the role of p21 in systemic autoimmunity, we
generated congenic p21
 
 
 
/
 
 
 
 lupus-susceptible BXSB mice
and assessed disease manifestations, immune homeostasis, and
 
the responses of T and B cells. Males were exclusively stud-
ied because severe early life lupuslike disease in this strain re-
quires the 
 
Yaa
 
 (Y chromosome accelerator of autoimmunity
and lymphoproliferation) susceptibility gene (13).
 
Reduced Hypergammaglobulinemia and Autoantibodies in
p21
 
 
 
/
 
 
 
 BXSB Mice.
 
Initial studies were performed to de-
termine the effects of p21 deficiency on autoimmune man-
ifestations. Control mice exhibited typical hypergamma-
globulinemia at 4 mo of age, whereas all IgG subclasses
were significantly lower in p21
 
 
 
/
 
 
 
 littermates, approaching
levels seen in C57BL/6 normal mice (Fig. 1 a). Antichro-
matin levels, predominantly of the IgG2a subclass, were
also high in the wild-type littermates. In contrast, antichro-
matin autoantibodies of all subclasses were greatly reduced
in the p21
 
 
 
/
 
 
 
 mice (Fig. 1 b).
 
Enhanced Survival and Reduced Kidney Disease in p21
 
 
 
/
 
 
 
BXSB Mice.
 
The mortality and immunopathology of the
control p21 /  littermates were similar to those of our male
BXSB colony, indicating sufficient backcrossing of the major
BXSB lupus susceptibility genes. In contrast, there was a dra-
matic reduction in mortality and GN in BXSB p21 /  mice.
Control BXSB males showed 50% mortality at 5.6 mo and
100% mortality by 6.3 mo, whereas  80% of p21 /  mice
were alive at 13 mo and  65% at 16.5 mo (Fig. 1 c). GN
(2.1   0.4 vs. 3.4   0.2; P   0.05), IgG deposit scores (1.5  
0.2 vs. 3.1   0.4; P   0.05) (Fig. 1 d), and blood urea nitro-
gen levels (1.1   0.1 vs. 3.2   0.2; P   0.05) were also sig-
nificantly reduced in 4-mo-old BXSB p21 /  mice. Thus,
p21 is clearly essential for the accelerated lupus in BXSB mice.
Fewer Total and Activated/Memory T and B Cells in p21 / 
BXSB Mice. The effects of p21 deficiency on in vivo au-
toimmune T and B cell homeostasis, proliferation, and
apoptosis were examined. The weights and cellular compo-
Figure 1. Decreased autoimmune disease in male
p21 /  BXSB mice. (a and b) Reduced serum poly-
clonal (left) and antichromatin (right) IgG subclasses in
4-mo-old male BXSB p21 /  mice (n     8 mice/
group; mean    SEM). (shaded bars) BXSB p21 / 
mice. (unshaded bars) p21 /  BXSB mice. For all
polyclonal and antichromatin total and subclass IgG levels,
P   0.05 for p21    versus p21   . (c) Increased cumula-
tive survival rates of p21 /  BXSB mice (P   0.0001).
Male BXSB p21 /  (n   16) and p21 /  (n   15) litter-
mates were followed for up to 500 d. ( ) BXSB p21 / 
mice. ( ) BXSB p21 /  mice. (d) Glomerular pathology
(top) and IgG deposits (bottom) of representative 4-mo-
old p21 /  and p21 /  mice. Increased segmental
mesangial proliferation and accumulation of periodic-acid
Schiff–positive mesangial matrix material were seen in
p21 /  mice, whereas p21 /  mice exhibited signifi-
cantly less glomerular damage, as well as decreased seg-
mental granular mesangial and capillary wall deposits of
IgG (top, 630 ; bottom, 400 ).p21 Deficiency Inhibits Systemic Autoimmunity 550
sition of spleen and LN are shown in Table I. Spleen weight
and total cell numbers as well as numbers of CD8  and acti-
vated/memory CD8 CD44hi T cells were unaffected by
the lack of p21, but, strikingly, total splenic CD4  and acti-
vated/memory CD4 CD44hi cells were significantly re-
duced (P   0.05). When spleen cells were examined for
preapoptotic cells, p21 /  mice had a significant twofold in-
crease in the number of Annexin V–binding CD4 CD44hi
T cells, which represented a fourfold increase in percentage
(16.3   2.1 vs. 4.0   0.8%; P   0.05; Table I). In contrast,
splenic B cells (CD19 ), activated (Table I, CD69 ), mem-
ory (CD27 ), B1a (CD5 ), follicular, and marginal zone B
cell populations (not depicted) were unaffected. BXSB male
mice also develop an expanded peripheral blood population
of unusual Mac-1  MHC class II  monocytes whose con-
tributions to disease remains unknown (35). However, the
frequency of these cells was equivalent in p21 /  and p21 / 
mice (20.3   1.3 vs. 19.2   2.1%).
For the LN, there were significant approximately five-
fold reductions in both weight and total cell numbers in
p21 /  mice at 4 mo as well as lower numbers of T and B
cells and their subsets (Table I, P   0.05). Notably, the
percentage of preapoptotic (Annexin V ) activated/mem-
ory CD4 CD44hi T cells was  2.6-fold higher in the
p21 /  versus p21 /  mice (21.5 vs. 8.2%; P   0.05). The
absolute number of intracellular IFN-   T cells was also
greatly reduced in LNs of p21-deficient mice (Table I).
Enhanced Cycling of Activated/Memory CD4 CD44hi T
Cells in p21 /  BXSB Mice. Analysis of in vivo prolifera-
tion indicated enhanced cycling of CD4  T cells in p21-
deficient animals, with significant increases in both total
Table I. Spleen and LN Analysis of BXSB p21    Mice
T cells (  106) B cells (  106)
Weight
Total 
(  106) CD4  CD4+CD44hi CD4+CD44hiAV+ CD4 IFN- + CD8+ CD8+CD44hi CD8+CD44hiAV+ CD19+ CD19+CD69+
Spleen
BXSB
p21   
 0.4   0.05 190.4   21.0 29.4   4.4 24.4   3.3 0.97   0.02 (4%)a ND 15.3   8.0 8.8   4.6 ND 126   14.4 9.1   2.2
BXSB
p21   
0.3   0.1 170.4   37.1 18   2.2b 11.7   1.4b  1.91   0.03b (16%)a ND 14.5   1.5 6.7   0.4 ND 102.7   20.5 6.0   1.3
LN
BXSB
p21   
0.5   0.11 249.2   21.0 75.6   9.9 45.1   6.4 3.7   0.2 (8%)a 16.6   2.2 25.3   5.0 14.8   2.6 2.2   0.6 117.8   2.5 5.3   1.9
BXSB
p21 / 
 0.1   0.04b 52   4.7b 15.3   3.2b 6.5   0.2b 1.4   0.1b (22%)a 3.7   1.0b  4.5   1.5b 1.7   0.4b  0.4   0.1b  27.2   4.1b 0.8   0.0.3b
Spleen and combined LN (axillary, inguinal, cervical, and mesenteric) weights (n   8 mice/group) are shown (mean   SEM g). T and B cell subsets
from p21    and p21    BXSB mice at 4 mo of age are indicated as total numbers (mean   SEM) of splenocytes or their respective subset (n   5
mice/group).
aPercent of CD4 CD44hi T cells that are AV .
bP   0.05 between p21    and p21    mice. ND, not determined.
Table II. Long-Term In Vivo BrdU Incorporation of T and B 
Cells in Male BXSB p21    and p21    Mice
BrdUhi
Cell population BXSB p21    BXSB p21   
%%
CD4  8.9   0.9 19.0   2.3a
CD4 CD44hi 24.2   2.0 36.5   3.2a
CD8  9.7   1.2 15.2   2.4
CD8 CD44hi 13.1   1.8 12.4   2.9
CD45R/B220  25.5   2.1 29.0   5.8
4-mo-old male BXSB p21 /  and p21    were fed BrdU in drinking
water for 9 d. T and B cells (B220 ) defined by FACS® as BrdUhi are
indicated as percentages of the listed cell populations.
aP   0.05 between male BXSB p21 /  and p21    mice (n   3).
Figure 2. Representative dis-
tribution of G0- versus G1-phase
in CD4 CD44hi T cells. Spleno-
cytes from 3-mo-old mice (n   4
animals/group) were stained
with antibodies to CD4 and
CD44, followed by sequential
incubation with Hoechst 33342
(DNA-binding dye) and Pyronin
Y (RNA-binding dye) and ana-
lyzed by flow cytometry. Pyronin
Y staining of G0/G1-phase
CD4 CD44hi T cells from p21 / 
and p21 /  BXSB mice is shown
(P   0.05).Lawson et al. 551
CD4 BrdUhi and CD4 CD44hiBrdUhi T cells, whereas
frequencies of cycling CD8  T cells and B cells were unal-
tered (Table II).
To further define the in vivo cycling characteristics of
p21-deficient CD4 CD44hi T cells, the frequency of cells
in G0- versus G1-phase was determined by the RNA indi-
cator dye Pyronin Y. Strikingly, the frequency of Pyronin
Yhi (G1-phase) CD4 CD44hi T cells was significantly
higher in p21-deficient mice versus BXSB male controls
(86.2   2.4% vs. 44.3   5.8%; Fig. 2, P   0.05).
Enhanced Proliferation and Apoptosis of p21 /  T Cells.
Previous in vitro analyses with p21 /  T cells from nonau-
toimmune mice showed increased proliferation compared
with wild-type T cells (36, 37). Similarly, BXSB p21 /  T
cells showed enhanced proliferation compared with wild-
type T cells (P    0.05) after engagement of CD3 and
CD28, with no apparent alteration of the TCR-induced ac-
tivation threshold (Fig. 3 a). Increased proliferation was not
attributed to enhanced TCR expression, which was equiva-
lent between the two types of T cells before and after stim-
ulation (unpublished data). These findings were further sup-
ported by time-kinetic analysis showing equal proliferation
of p21 /  and wild-type T cells up to 24 h, but significantly
greater proliferation of p21 /  T cells by 72 h (Fig. 3 b). In-
terestingly, p21 /  T cell proliferation declined faster than
control T cells, reaching baseline levels by  120 h after
stimulation compared with  150 h for the p21 /  cells,
suggesting increased apoptosis by the p21-deficient cells.
To test whether p21 /  T cells undergo enhanced apop-
tosis, we assessed in vitro AICD by incubating these cells for
48 h with soluble anti-CD3, followed by religation with
plate-bound anti-CD3 (18). At 24 h after religation, the
percentage of Annexin V /Propidium Iodide (AV PI ,
preapoptotic) CD4  T cells was similar for p21 /  and
p21 /  cells. However, by 48 h, the p21 /  cells showed a
greater percentage of preapoptotic cells, which was more
pronounced by 72 h (Fig. 3 c, P   0.05). Similar results
were obtained with CD8  T cells (not depicted).
To confirm that the absence of p21 was responsible for the
increased proliferation and apoptosis, the effect of Penetratin-
conjugated p21 AS oligonucleotides on T cell proliferation
and AICD was assessed. Wild-type T cells transfected with
either of two p21-specific AS oligonucleotides, but not with
a control oligonucleotide, showed significantly increased pro-
liferation (Fig. 3 d) and apoptosis (Fig. 3 e), approaching the
levels of the p21 /  cells (P   0.05). Similar results were ob-
served with CD8  T cells (unpublished data). The oligonu-
cleotides had no discernible effect on viability, and Western
blot analysis confirmed that the two specific p21 AS oligonu-
Figure 3. Enhanced proliferation and apoptosis of p21 /  T cells from
male BXSB mice. (a) Increased proliferation of p21 /  T cells after in
vitro cross-linking of antigen receptors. LN cells (n   3 mice/group)
were stimulated with increasing concentrations of plate-bound anti-CD3
(0.1–20  g/ml) plus 5  g/ml of soluble anti-CD28 antibodies and assessed
for [3H]thymidine incorporation at 72 h (mean   SEM cpm). (shaded
bars) BXSB p21 /  mice. (unshaded bars) p21 /  BXSB mice. (b) Kinetics
of in vitro proliferation. LN cells (n   3 mice/group) were stimulated
with 10  g/ml of plate-bound anti-CD3 plus 5  g/ml of soluble anti-
CD28 antibodies and assessed for [3H]thymidine incorporation at the
indicated time points. Results are representative of two independent exper-
iments (n   3 mice/group). ( ) BXSB p21 /  mice. ( ) BXSB p21 / 
mice. (c) Increased AICD of p21 /  T cells. T cell were stimulated with
0.5  g/ml of soluble anti-CD3 for 48 h followed by TCR religation with
10  g/ml of plate-bound anti-CD3 (n   3 mice/group). Percent of
apoptotic (Annexin V PI ) CD4  T cells was determined by FACS®.
Similar results were obtained with CD8  T cells. ( ) BXSB p21 / 
mice. ( ) BXSB p21 /  mice. (d) Increased proliferation of wild-type
BXSB T cells treated with p21 AS oligonucleotides. LN cells (n   4
mice/group) were stimulated with 10  g/ml of plate-bound anti-CD3
plus 5  g/ml of soluble anti-CD28 antibodies in the presence of either
p21 AS or control oligonucleotides (all AS oligonucleotides at 400 nM)
and assessed for [3H]thymidine incorporation (mean   SEM cpm). (e) In-
creased AICD of wild-type BXSB T cells treated with p21 AS oligonu-
cleotides. Wild-type BXSB T cells were stimulated with 0.5  g/ml of
soluble anti-CD3 followed by TCR religation with 10  g/ml of plate-
bound anti-CD3 in the constant presence of p21 AS or control oligonu-
cleotides (400 nM; n   3 mice/group). ( ) AS oligo no. 1. ( ) AS oligo
no. 2. ( ) Control oligonucleotide. (e, inset) Western blot analysis of
wild-type BXSB T cells treated with either p21 AS or control oligonucle-
otides. T cells were stimulated with 10  g/ml anti-CD3 and 5  g/ml
CD28 antibodies in the presence of AS or control oligonucleotides (400
nm). Whole cell lysates were analyzed by Western blot using anti-p21 and
antiactin antibodies. *, P   0.05 by Student’s t test.p21 Deficiency Inhibits Systemic Autoimmunity 552
cleotides, but not the control oligonucleotide, efficiently
blocked p21 protein expression (Fig. 3 e, inset).
Enhancement of the Extrinsic Pathway of Apoptosis in p21 / 
T Cells. Fas and FasL expression of anti-CD3– and anti-
CD28–activated p21 /  and p21 /  CD4 T cells was
equivalent (unpublished data). However, anti-Fas–induced
apoptosis of activated CD4 T cells was higher in p21-defi-
cient T cells (Fig. 4 a). Accordingly, kinetic studies
showed that the frequency of p21 /  T cells undergoing
AICD that had converted initiator procaspase 8 and effec-
tor procaspase 3 to active caspases was significantly higher
than wild-type cells at all time points (Fig. 4 b). Similarly,
loss of mitochondrial transmembrane potential was more
pronounced in p21 /  than p21 /  cells (Fig. 4 b). How-
ever, AICD was inhibited in both types of T cells by ei-
ther anti-FasL mAb (Fig. 4 c) or Fas/Fc (not depicted).
Thus, as expected, the Fas/FasL pathway is the primary
mediator of AICD in p21 /  and p21 /  T cells, but the
CD95 signaling cascade and associated events are amplified
in p21 /  cells.
Participation of the Intrinsic Pathway of Apoptosis. Al-
though the extrinsic CD95-mediated apoptosis pathway is
generally sufficient for AICD, depending on cell type and/or
signal strength, the intrinsic pathway may facilitate this pro-
cess (38–40). p21 /  T cells cultured with anti-CD3 and
anti-CD28 for 48 h expressed 1.9-fold more p53 and 1.7-fold
less Bcl-2 protein than control cells. Although Bax expression
was unaltered, the ratio of Bax/Bcl-2 shifted moderately to-
ward the proapoptotic Bax (5.3 in p21 /  vs. 3.1 in p21 / )
(Fig. 5; P   0.05). In addition, activated wild-type T cells
cultured in the presence of transfecting p21 AS oligonucle-
otides showed a 1.7-fold decrease in Bcl-2 and, in this case, a
1.9-fold increase in Bax expression, resulting in a more pro-
nounced shift in the Bax/Bcl-2 ratio (8.1; P   0.05).
Enhanced Proliferation and Apoptosis of p21 /  B Cells.
As reported for T cells, B cells from lupus-predisposed mice
have also been shown to be both arrested in G1 and apopto-
sis resistant (10, 41). Indeed, we detected high p21 levels in
male, but not female, B cells (Fig. 6 a). Accordingly, activa-
tion with anti-IgM plus IL-4 induced higher proliferation
(Fig. 6 b; P   0.05), and cross-linking with anti-IgM re-
sulted in accelerated and enhanced apoptosis of p21 / 
compared with wild-type B cells (Fig. 6 c; P   0.05).
Figure 4. Enhanced Fas/FasL-
mediated apoptosis of p21 / 
T cells from male BXSB mice.
(a) Increased anti-Fas induced
apoptosis of p21 /  T cells. LN
cells (n    3 mice/group) were
first stimulated with 10  g/ml of
soluble anti-CD3 and 5  g/ml
CD28 for 48 h and then with 5
 g/ml anti-Fas antibody and
analyzed for percentage of apop-
totic (Annexin V PI ) CD4  T
cells. ( ) BXSB p21 /  mice.
( ) BXSB p21 /  mice. *, P  
0.05. (b) Increased caspase 8 and
3 activation and reduced mito-
chrondrial membrane potential
(  m) in p21 /  T cells after
induction of AICD. T cells (n   3
mice/group) were stimulated
with 0.1  g/ml of soluble anti-
CD3, religated with 10  g/ml of
plate-bound anti-CD3, and ana-
lyzed by FACS® for activation of
caspases 8 and 3 and for change
in mitochondrial transmembrane
potential. The percentage of cells
expressing activated caspases 8 or
3 and reduced   m is indicated
(mean   SEM). P   0.05 be-
tween p21    and p21    for all time points shown. (c) Fas blockade inhibits AICD of p21 /  and p21 /  T cells. T cells (n   3 mice/group) were
stimulated with 0.1  g/ml of soluble anti-CD3 for 48 h, religated with 10  g/ml of plate-bound anti-CD3 in the presence or absence of 10  g/ml of
blocking anti-FasL antibody, and analyzed for Annexin V positivity. Similar inhibition was also observed after treatment with Fas-blocking soluble Fas/
Fc. ( ) BXSB p21 /  mice plus anti-FasL. ( ) BXSB p21 /  mice plus anti-FasL. ( ) BXSB p21 /  mice. ( ) BXSB p21 /  mice. *, P   0.05 for
untreated (  or  ) versus anti-FasL–treated groups (  or  ) at 48 and 72 h, and for untreated p21    ( ) versus p21    ( ) mice at 72 h.
Figure 5. Participation of the intrinsic
pathway of apoptosis in p21 /  T cells from
male BXSB mice. Increased p53 and reduced
Bcl-2 expression in activated p21 /  T cells.
T cells (n   5 mice/group) were activated
with 10  g/ml anti-CD3 plus 5  g/ml
anti-CD28, and lysates were analyzed by
Western blot.Lawson et al. 553
Enhanced Primary, but Reduced Late Secondary, TD IgG
Responses in p21 /  BXSB Mice. When TD antibody re-
sponses to TNP-KLH were examined, p21 /  mice
showed fivefold higher primary IgG (Fig. 6 d) and margin-
ally increased IgM (not depicted) responses at day 14 com-
pared with wild-type mice. However, 7 d after rechallenge,
the secondary IgG response increased twofold in p21 / 
versus 12-fold in the wild-type mice. Notably, the second-
ary response in the p21 /  mice precipitously declined
thereafter to almost baseline levels by day 35, whereas the
decline was gradual in the wild-type mice, a finding com-
patible with enhanced AICD in the p21 /  cells.
Fewer Quiescent Stem Cells in p21 /  BXSB Mice. We
also determined whether p21 /  BXSB mice have reduced
numbers of quiescent stem cells by analyzing the RNA
content of Lin Sca-1  bone marrow cells using Pyronin Y
staining. Similar to previous papers with p21 /  normal
background mice (30), autoimmune p21 /  mice had
fewer stem cells in G0-phase than controls (7.8   0.4% vs.
12.2   1.25%; P   0.01), perhaps reducing the renewal
capacity of these cells and consequent generation of precur-
sor T and B cells.
Discussion
Herein, we demonstrate that deletion of the CDKI p21
significantly reduced serologic, cellular, and histologic dis-
ease manifestations and increased survival of lupus-prone
BXSB mice. Furthermore, there was reduced accumulation
of proliferation- and apoptosis-resistant T and B cells
through a novel mechanism involving enhanced entry of
these cells into the cell cycle followed by apoptotic death.
These findings clearly show that accumulation of replica-
tion/apoptosis-resistant T and B cells in this spontaneous
lupus model is dependent on increased p21 expression, and
suggest that these cells contribute significantly to the au-
toimmune and inflammatory processes that are critical for
disease pathogenesis.
Classically, p21 inhibits cell cycle entry by blocking for-
mation of active cyclin–CDK complexes. However, more
recently identified p21 functions, including inhibition of
DNA replication through proliferating cell nuclear antigen
binding, repression of E2F, interference with c-Myc, con-
trol of certain transcription coactivators, and other interac-
tions may also be involved in cell cycle blockade (21, 24).
Growth factors initiate and maintain the entry of cells
from G1 to S phase in the cell cycle (42). Mitogen-activated
protein kinase (MAPK) signaling induces D cyclins, result-
ing in activation of CDK4 and CDK6, and progression of
cells through G1. However, MAPK signaling has also been
shown to induce CDKIs, including p21, and growth arrest
(43–45). Thus, it has been suggested that strong or sus-
tained activation of MAPK signaling leads to induction of
CDKIs and cell cycle arrest, whereas transient activation
promotes cell cycle.
This cellular activation model provides a possible expla-
nation for the accumulation of activated/memory pheno-
type CD4  T cells in lupus (Fig. 7). We hypothesize that
genetic susceptibility predisposes lupus T cells to hyperre-
spond through a variety of mechanisms, such as increased
antigen presentation or lack of regulatory signaling. Many
of these mechanisms have been revealed recently by analy-
ses of spontaneous as well as gene knockout and transgenic
mice with lupuslike disease (46, 47). This enhanced activa-
Figure 6. Enhanced prolifera-
tion and apoptosis, and reduced
late secondary immunoglobulin
responses of p21 /  B cells from
male BXSB mice. (a) Increased p21 expression in B cells from older male BXSB mice. Sorted B
cells (CD19 ) from 3-mo-old wild-type male or female BXSB mice (n   5 mice/group) were
analyzed by RNase protection assay for expression of p21 and L32 (control). (b) Increased prolif-
eration of p21 /  B cells after IgM cross-linking. Splenocytes (n   3 mice/group) were stimu-
lated with 10  g/ml of soluble goat F(ab )2 anti–mouse IgM in the presence of IL-4 and assessed
for [3H]thymidine incorporation (mean   SEM cpm). ( ) BXSB p21 /  mice. ( ) BXSB p21 / 
mice. (c) Enhanced AICD of p21 /  B cells. Annexin V positivity of B cells was assessed after
anti-IgM stimulation with 10  g/ml of soluble goat F(ab )2 anti–mouse IgM (n   3 mice/group).
( ) BXSB p21 /  mice. ( ) BXSB p21 /  mice. (d) Anti-TNP antibody levels after primary and
secondary immunizations. 2-mo-old male BXSB p21 /  and p21 /  mice (n   4 mice/group)
were injected s.c. with 100  g TNP-KLH emulsified in CFA. Secondary responses were assessed
by boosting mice s.c. with 100  g TNP-KLH in saline on day 21. Mice were bled at the indi-
cated times, and serum was analyzed by ELISA. ( ) BXSB p21 /  mice. ( ) BXSB p21 /  mice.
*, P   0.05 by Student’s t test.p21 Deficiency Inhibits Systemic Autoimmunity 554
tion, together with continuous stimulation by ever-present
self-antigens, will lead to repeated interconversions of T
cells from effector to memory and vice versa. Selection of
high affinity memory T cells results in increased MAPK
signaling, induction of CDKIs, and finally accumulation of
memory phenotype T cells that are replication and apop-
tosis resistant. Potential experimental analogies are resis-
tance to cell cycle progression of T cells cultured for pro-
longed periods with anti-CD3 antibody (48) and high
concentrations of superantigen (49) or specific antigen
(50). In further support of this hypothesis, HLA-A1–spe-
cific T cells repeatedly stimulated in vitro with antigen to
emulate possible autoimmune responses converted to ef-
fector/memory phenotype cells resistant to CD95-medi-
ated AICD (51). As discussed here, absence of the pancy-
clin inhibitor p21 reduces the likelihood of cells attaining
this G0/G1 arrested state, and their accumulation. It is sig-
nificant that despite the multiple pancyclin inhibitors (p21,
p27, and p57), deletion of p21 can accomplish this effect,
implying that functional redundancy among these mole-
cules is only partial.
Extensive data have shown previously that p21 inhibits
apoptosis of various cell types by directly affecting expres-
sion/function of several molecules involved in this process
(24, 52). We demonstrated that p21 deletion amplified T
cell AICD by promoting the extrinsic pathway of apopto-
sis. Thus, in the absence of p21, Fas/FasL-mediated apop-
tosis was enhanced, concurrent with increased conversion
of procaspases 8 and 3 to active caspases, and loss of mito-
chondrial transmembrane potential. Moreover, wild-type
T cells behaved similarly to p21-deficient cells when
transfected with p21 AS oligonucleotides. The results
clearly establish that p21 is a significant inhibitor of Fas/
FasL-mediated T cell apoptosis. Enhanced sensitization of
glioma cells to CD95-mediated apoptosis with p21 AS
oligonucleotides associated with increased caspase 8 and 3
activation has been shown previously (40). We also ob-
served increased apoptosis of anti-IgM cross-linked p21 / 
B cells, in agreement with studies showing diminished
G1-arrest and increased apoptosis of B cells treated with
p21 AS oligonucleotides (53).
A potential biochemical explanation for the increased ac-
tivation of procaspase 3 may be provided by the series of
observations by Suzuki et al., who reported that p21 re-
leased from the CDK4/6 complex by survivin translocates
to the mitochondria, binds to a putative mitochondrial
adaptor protein, and sequesters procaspase 3 (54–57).
Moreover, because p21 binds to the cleavage site of pro-
caspase 3, conversion to the p17 active fragment is also re-
duced, thus impeding Fas-mediated apoptosis. In addition,
evidence has been presented that active caspase 3 can cleave
p21, reducing its inhibitory effects and accelerating apopto-
sis (58–61). Increases in proximal caspase 8 activation of
p21-deficient cells undergoing AICD might be attributed
to less interference with procaspase 8 cleavage (24), or to a
feedback effect mediated by the increased levels of acti-
vated caspase 3 (40).
Depending on cell type and/or signal intensity, the ex-
trinsic and intrinsic pathways of apoptosis may converge
(38, 39). We found that activated p21    T cells had only a
moderate increase in p53 levels and a slight shift in the ratio
of Bax/Bcl-2 toward the proapoptotic Bax. Stabilization of
p53 and inversion of the Bcl-2/Bax ratio has also been re-
ported in carcinoma cells undergoing chemotherapeutic
drug-induced apoptosis (62). However, it appears that the
intrinsic pathway plays a minor role, if any, in the en-
hanced AICD of p21    T cells.
A slight reduction in the percentage (7.8 vs. 12.2%) of
quiescent G0-phase hematopoietic stem cells in p21 / 
BXSB mice was also observed. However, this was not asso-
ciated with hematopoietic precursor insufficiency, consis-
tent with a previous paper in which p21 /  bone marrow
cells that required three serial passages before significant
stem cell deficiency was observed (30). Furthermore, the
reduction of T and B cells was limited to only certain lym-
phoid organs and cell subsets. Thus, it is highly unlikely
that the slight decrease in percentage of quiescent stem cells
plays a significant role in the reduction in activated/mem-
ory T and B cells and autoimmune disease in p21 /  mice.
One of the most striking findings in this work is the dif-
ference in TD antibody responses of p21 /  and wild-type
BXSB mice. In the primary response, p21 /  mice showed
Figure 7. T cell senescence and p21 in systemic
autoimmunity. In lupus-prone mice, the accumu-
lated activated/memory CD4  T cells are in a
state resembling replicative senescence. We
hypothesize that repeated stimulation of CD4 
T cells (depicted by the hypothetical movement
of cells from the memory to effector compart-
ments) by self-antigens (Ag) leads to resistance
to proliferation and apoptosis (senescent-like
cell), due in large part to increased levels of
CDKIs. Senescent cells are metabolically active
and can produce proinflammatory cytokines. As
shown in this work, the gradual accumulation
of these activated/memory phenotype CD4  T
cells and subsequent development of autoim-
munity is dependent on p21. Furthermore, our
data indicate that the fraction of activated/memory CD4 CD44hi T cells that escape AICD in wild-type autoimmune mice (because of increased CDKIs)
do not accumulate in G0/G1-phase in p21-deficient mice; instead, they proliferate and become susceptible to Fas-mediated apoptosis. Thus, the lack of
p21 appears to restore homeostasis of autoreactive CD4 CD44hi T cells by preventing their transition to a senescent-like state.Lawson et al. 555
much higher IgG levels, whereas in the secondary re-
sponse, the antibody levels declined more rapidly com-
pared with wild-type mice. The enhanced primary anti-
body response in p21 /  mice is likely due to accelerated
proliferation of helper T cells, whereas the rapid reduction
in the secondary response is likely caused by increased
AICD. This finding is compatible with our hypothesis that,
under conditions of sustained T cell stimulation by constant
exposure to self-antigens, lack of p21 leads to enhanced
proliferation and apoptosis of self-reactive helper T cells,
thereby reducing autoantibody responses.
Our findings contrast sharply with an initial report that
older female, but not male, p21 /  mice of mixed 129/Sv  
C57BL/6 (129   B6) background develop severe lupuslike
features (36). Subsequent analyses by us with a different
group of p21 /  mixed-background 129   B6 mice and,
more significantly, with female BXSB p21 /  mice con-
taining all lupus-predisposing genes except the Yaa,
showed no appreciable induction of autoimmune disease
(34, 37). Several papers have documented that the 129  
B6 mixed genomes spontaneously develop signs of systemic
autoimmunity with low levels of GN, especially in females
of advanced age (37, 63–66). Therefore, systemic autoim-
munity in gene-deleted 129   B6 mice should be carefully
controlled by performing a sufficient number of back-
crosses to attain genetic homogeneity, and should include
wild-type littermates. The present paper makes it clear that
modulation of the cell cycle pathway by deleting the CDKI
p21 inhibits the development of systemic autoimmunity.
This is further supported by our recent finding that defi-
ciency in another CDKI (i.e., p27) also results in reduction
of lupuslike disease in male BXSB mice (unpublished data).
Although our work focused on male BXSB lupus mice,
expansion of activated/memory phenotype T cell popula-
tions is common to other lupus strains (5, 67), and is ob-
served in human systemic lupus erythematosus (68, 69).
Accumulation of G0/G1-arrested T cell populations has also
been observed in other autoimmune diseases, such as rheu-
matoid arthritis (70) and insulin-dependent diabetes (71,
72), and even in aging (73), suggesting that these cells may
also contribute to the pathogenesis of these diseases and to
immune senescence.
The present paper raises the possibility that efforts to
block the activity of CDKIs may be a means to intervene in
systemic autoimmunity and other immune-related disor-
ders. The primary contribution of p21 in disease pathogen-
esis, and the relatively benign consequences of p21 defi-
ciency (24), makes it a particularly promising therapeutic
target. Blockade of p21 and possibly other CDKIs could be
a novel approach that, instead of inhibiting, promotes pro-
liferation and hence apoptosis of the accumulated autoreac-
tive T and B cells. This may be a particularly powerful
strategy for eliminating disease-promoting cells in advanced
autoimmune diseases.
We thank J.D. Kuan, L. Simpson, V. Clifton, S. Koundouris, and
A. Szydlik for their technical assistance, M.K. Occhipinti and J.
Kuhns for their editorial assistance, and Drs. J. Sprent, G. Bokoch,
and S. Reed for manuscript review and comments. 
This is publication number 14384-IMM from the Department
of Immunology at the The Scripps Research Institute. The work
herein was supported in part by U.S. Public Health Service grants
AR32103, AG15061, AR39555, and AR42242, and National In-
stitutes of Health training grant AG00080.
Submitted: 30 September 2003
Accepted: 18 December 2003
References
1. Sprent, J., and D.F. Tough. 1994. Lymphocyte life-span and
memory. Science. 265:1395–1400.
2. Ahmed, R., and D. Gray. 1996. Immunological memory and
protective immunity: understanding their relation. Science.
272:54–60.
3. Theofilopoulos, A.N., and D.H. Kono. 1999. Murine lupus
models: gene-specific and genome-wide studies. In Systemic
Lupus Erythematosus. R.G. Lahita, editor. Academic Press,
San Diego. 145–181.
4. Chu, E.B., D.N. Ernst, M.V. Hobbs, and W.O. Weigle. 1994.
Maturational changes in CD4  cell subsets and lymphokine
production in BXSB mice. J. Immunol. 152:4129–4138.
5. Sabzevari, H., S. Propp, D.H. Kono, and A.N. Theofilopou-
los. 1997. G1 arrest and high expression of cyclin kinase and
apoptosis inhibitors in accumulated activated/memory phe-
notype CD4  cells of older lupus mice. Eur. J. Immunol. 27:
1901–1910.
6. Campisi, J. 1996. Replicative senescence: an old lives’ tale?
Cell. 84:497–500.
7. Noda, A., Y. Ning, S.F. Venable, O.M. Pereira-Smith, and
J.R. Smith. 1994. Cloning of senescent cell-derived inhibi-
tors of DNA synthesis using an expression screen. Exp. Cell
Res. 211:90–98.
8. Sayama, K., Y. Shirakata, K. Midorikawa, Y. Hanakawa, and K.
Hashimoto. 1999. Possible involvement of p21 but not of p16
or p53 in keratinocyte senescence. J. Cell. Physiol. 179:40–44.
9. Prud’homme, G.J., D.H. Kono, and A.N. Theofilopoulos.
1995. Quantitative polymerase chain reaction analysis reveals
marked overexpression of interleukin-1 , interleukin-1 and
interferon-  mRNA in the lymph nodes of lupus-prone
mice. Mol. Immunol. 32:495–503.
10. Kozono, Y., B.L. Kotzin, and V.M. Holers. 1996. Resting B
cells from New Zealand Black mice demonstrate a defect in
apoptosis induction following surface IgM ligation. J. Immu-
nol. 156:4498–4503.
11. Wither, J.E., A.D. Paterson, and B. Vukusic. 2000. Genetic
dissection of B cell traits in New Zealand black mice. The
expanded population of B cells expressing up-regulated co-
stimulatory molecules shows linkage to Nba2. Eur. J. Immu-
nol. 30:356–365.
12. Blossom, S., E.B. Chu, W.O. Weigle, and K.M. Gilbert.
1997. CD40 ligand expressed on B cells in the BXSB mouse
model of systemic lupus erythematosus. J. Immunol. 159:
4580–4586.
13. Theofilopoulos, A.N., and F.J. Dixon. 1985. Murine models
of systemic lupus erythematosus. Adv. Immunol. 37:269–390.
14. Green, D.R., and D.W. Scott. 1994. Activation-induced
apoptosis in lymphocytes. Curr. Opin. Immunol. 6:476–487.
15. Sherr, C.J. 1996. Cancer cell cycles. Science. 274:1672–1677.
16. Renno, T., A. Attinger, S. Locatelli, T. Bakker, S. Vacheron,
and H.R. MacDonald. 1999. Cutting edge: apoptosis of super-p21 Deficiency Inhibits Systemic Autoimmunity 556
antigen-activated T cells occurs preferentially after a discrete
number of cell divisions in vivo. J. Immunol. 162:6312–6315.
17. Boehme, S.A., and M.J. Lenardo. 1993. Propriocidal apopto-
sis of mature T lymphocytes occurs at S phase of the cell cy-
cle. Eur. J. Immunol. 23:1552–1560.
18. Radvanyi, L.G., Y. Shi, G.B. Mills, and R.G. Miller. 1996.
Cell cycle progression out of G1 sensitizes primary-cultured
nontransformed T cells to TCR-mediated apoptosis. Cell.
Immunol. 170:260–273.
19. Fotedar, R., J. Flatt, S. Gupta, R.L. Margolis, P. Fitzgerald,
H. Messier, and A. Fotedar. 1995. Activation-induced T-cell
death is cell cycle dependent and regulated by cyclin B. Mol.
Cell. Biol. 15:932–942.
20. Sherr, C.J., and J.M. Roberts. 1999. CDK inhibitors: positive
and negative regulators of G1-phase progression. Genes Dev.
13:1501–1512.
21. Dotto, G.P. 2000. p21(WAF1/Cip1): more than a break to
the cell cycle? Biochim. Biophys. Acta. 1471:M43–M56.
22. Harada, K., and G.R. Ogden. 2000. An overview of the cell
cycle arrest protein, p21(WAF1). Oral Oncol. 36:3–7.
23. Vousden, K.H. 2000. p53: death star. Cell. 103:691–694.
24. Gartel, A.L., and A.L. Tyner. 2002. The role of the cyclin-
dependent kinase inhibitor p21 in apoptosis. Mol. Cancer
Ther. 1:639–649.
25. Hobeika, A.C., W. Etienne, B.A. Torres, H.M. Johnson,
and P.S. Subramaniam. 1999. IFN-gamma induction of
p21(WAF1) is required for cell cycle inhibition and suppres-
sion of apoptosis. J. Interferon Cytokine Res. 19:1351–1361.
26. Xaus, J., M. Cardo, A.F. Valledor, C. Soler, J. Lloberas, and
A. Celada. 1999. Interferon gamma induces the expression of
p21waf-1 and arrests macrophage cell cycle, preventing in-
duction of apoptosis. Immunity. 11:103–113.
27. Deng, C., P. Zhang, J.W. Harper, S.J. Elledge, and P. Leder.
1995. Mice lacking p21CIP1/WAF1 undergo normal devel-
opment, but are defective in G1 checkpoint control. Cell. 82:
675–684.
28. Le, L.Q., J.H. Kabarowski, Z. Weng, A.B. Satterthwaite,
E.T. Harvill, E.R. Jensen, J.F. Miller, and O.N. Witte. 2001.
Mice lacking the orphan G protein-coupled receptor G2A
develop a late-onset autoimmune syndrome. Immunity. 14:
561–571.
29. Lawson, B.R., G.J. Prud’homme, Y. Chang, H.A. Gardner,
J. Kuan, D.H. Kono, and A.N. Theofilopoulos. 2000. Treat-
ment of murine lupus with cDNA encoding IFN- R/Fc. J.
Clin. Invest. 106:207–215.
30. Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Domb-
kowski, M. Sykes, and D.T. Scadden. 2000. Hematopoietic
stem cell quiescence maintained by p21cip1/waf1. Science.
287:1804–1808.
31. Okahashi, N., Y. Murase, T. Koseki, T. Sato, K. Yamato,
and T. Nishihara. 2001. Osteoclast differentiation is associ-
ated with transient upregulation of cyclin-dependent kinase
inhibitors p21(WAF1/CIP1) and p27(KIP1). J. Cell. Biochem.
80:339–345.
32. Fujio, Y., K. Guo, T. Mano, Y. Mitsuuchi, J.R. Testa, and
K. Walsh. 1999. Cell cycle withdrawal promotes myogenic
induction of Akt, a positive modulator of myocyte survival.
Mol. Cell. Biol. 19:5073–5082.
33. Park, C.L., R.S. Balderas, T.M. Fieser, J.H. Slack, G.J.
Prud’Homme, F.J. Dixon, and A.N. Theofilopoulos. 1983.
Isotypic profiles and other fine characteristics of immune re-
sponses to exogenous thymus-dependent and -independent
antigens by mice with lupus syndromes. J. Immunol. 130:
2161–2167.
34. Lawson, B.R., D.H. Kono, and A.N. Theofilopoulos. 2002.
Deletion of p21 (WAF-1/Cip1) does not induce systemic au-
toimmunity in female BXSB mice. J. Immunol. 168:5928–5932.
35. Wofsy, D., C.E. Kerger, and W.E. Seaman. 1984. Monocy-
tosis in the BXSB model for systemic lupus erythematosus. J.
Exp. Med. 159:629–634.
36. Balomenos, D., J. Martin-Caballero, M.I. Garcia, I. Prieto,
J.M. Flores, M. Serrano, and A.C. Martinez. 2000. The cell
cycle inhibitor p21 controls T-cell proliferation and sex-
linked lupus development. Nat. Med. 6:171–176.
37. Santiago-Raber, M.L., B.R. Lawson, W. Dummer, M.
Barnhouse, S. Koundouris, C.B. Wilson, D.H. Kono, and
A.N. Theofilopoulos. 2001. Role of cyclin kinase inhibitor
p21 in systemic autoimmunity. J. Immunol. 167:4067–4074.
38. Hengartner, M.O. 2000. The biochemistry of apoptosis. Na-
ture. 407:770–776.
39. Krammer, P.H. 2000. CD95’s deadly mission in the immune
system. Nature. 407:789–795.
40. Glaser, T., B. Wagenknecht, and M. Weller. 2001. Identifi-
cation of p21 as a target of cycloheximide-mediated facilita-
tion of CD95-mediated apoptosis in human malignant
glioma cells. Oncogene. 20:4757–4767.
41. Blossom, S.J., and K.M. Gilbert. 2000. B cells from autoim-
mune BXSB mice are hyporesponsive to signals provided by
CD4  T cells. Immunol. Invest. 29:287–297.
42. Blagosklonny, M.V. 2003. Cell senescence and hypermitoge-
nic arrest. EMBO Rep. 4:358–362.
43. Marshall, C.J. 1995. Specificity of receptor tyrosine kinase
signaling: transient versus sustained extracellular signal-regu-
lated kinase activation. Cell. 80:179–185.
44. Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and
M. McMahon. 1997. Raf-induced proliferation or cell cycle
arrest is determined by the level of Raf activity with arrest
mediated by p21Cip1. Mol. Cell. Biol. 17:5598–5611.
45. Sewing, A., B. Wiseman, A.C. Lloyd, and H. Land. 1997.
High-intensity Raf signal causes cell cycle arrest mediated by
p21Cip1. Mol. Cell. Biol. 17:5588–5597.
46. Kono, D.H., R. Baccala, and A.N. Theofilopoulos. 2004.
Genes and genetics of murine lupus. In Systemic Lupus
Erythematosus. R.G. Lahita, editor. Academic Press, San Di-
ego. In press.
47. Vratsanos, G.S., S. Jung, Y.M. Park, and J. Craft. 2001.
CD4( ) T cells from lupus-prone mice are hyperresponsive
to T cell receptor engagement with low and high affinity
peptide antigens: a model to explain spontaneous T cell acti-
vation in lupus. J. Exp. Med. 193:329–337.
48. Andris, F., M. Van Mechelen, F. De Mattia, E. Baus, J. Ur-
bain, and O. Leo. 1996. Induction of T cell unresponsiveness
by anti-CD3 antibodies occurs independently of co-stimula-
tory functions. Eur. J. Immunol. 26:1187–1195.
49. Miethke, T., C. Wahl, H. Gaus, K. Heeg, and H. Wagner.
1994. Exogenous superantigens acutely trigger distinct levels
of peripheral T cell tolerance/immunosuppression: dose–
response relationship. Eur. J. Immunol. 24:1893–1902.
50. Gilbert, K.M., and W.O. Weigle. 1993. Th1 cell anergy and
blockade in G1a phase of the cell cycle. J. Immunol. 151:
1245–1254.
51. Strauss, G., I. Knape, I. Melzner, and K.M. Debatin. 2003.
Constitutive caspase activation and impaired death-inducing
signaling complex formation in CD95-resistant, long-term ac-
tivated, antigen-specific T cells. J. Immunol. 171:1172–1182.
52. Poluha, W., D.K. Poluha, B. Chang, N.E. Crosbie, C.M.Lawson et al. 557
Schonhoff, D.L. Kilpatrick, and A.H. Ross. 1996. The cy-
clin-dependent kinase inhibitor p21 (WAF1) is required for
survival of differentiating neuroblastoma cells. Mol. Cell. Biol.
16:1335–1341.
53. Marches, R., R. Hsueh, and J.W. Uhr. 1999. Cancer dor-
mancy and cell signaling: induction of p21(waf1) initiated by
membrane IgM engagement increases survival of B lym-
phoma cells. Proc. Natl. Acad. Sci. USA. 96:8711–8715.
54. Suzuki, A., Y. Tsutomi, K. Akahane, T. Araki, and M. Mi-
ura. 1998. Resistance to Fas-mediated apoptosis: activation of
caspase 3 is regulated by cell cycle regulator p21WAF1 and
IAP gene family ILP. Oncogene. 17:931–939.
55. Suzuki, A., Y. Tsutomi, M. Miura, and K. Akahane. 1999.
Caspase 3 inactivation to suppress Fas-mediated apoptosis:
identification of binding domain with p21 and ILP and inac-
tivation machinery by p21. Oncogene. 18:1239–1244.
56. Suzuki, A., Y. Tsutomi, N. Yamamoto, T. Shibutani, and K.
Akahane. 1999. Mitochondrial regulation of cell death: mito-
chondria are essential for procaspase 3-p21 complex formation
to resist Fas-mediated cell death. Mol. Cell. Biol. 19:3842–3847.
57. Suzuki, A., T. Ito, H. Kawano, M. Hayashida, Y. Hayasaki,
Y. Tsutomi, K. Akahane, T. Nakano, M. Miura, and K.
Shiraki. 2000. Survivin initiates procaspase 3/p21 complex
formation as a result of interaction with Cdk4 to resist Fas-
mediated cell death. Oncogene. 19:1346–1353.
58. Gervais, J.L., P. Seth, and H. Zhang. 1998. Cleavage of CDK
inhibitor p21(Cip1/Waf1) by caspases is an early event dur-
ing DNA damage-induced apoptosis. J. Biol. Chem. 273:
19207–19212.
59. Levkau, B., H. Koyama, E.W. Raines, B.E. Clurman, B.
Herren, K. Orth, J.M. Roberts, and R. Ross. 1998. Cleavage
of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endo-
thelial cells through activation of Cdk2: role of a caspase cas-
cade. Mol. Cell. 1:553–563.
60. Park, J.A., K.W. Kim, S.I. Kim, and S.K. Lee. 1998. Caspase
3 specifically cleaves p21WAF1/CIP1 in the earlier stage of
apoptosis in SK-HEP-1 human hepatoma cells. Eur. J. Bio-
chem. 257:242–248.
61. Zhang, Y., N. Fujita, and T. Tsuruo. 1999. Caspase-mediated
cleavage of p21Waf1/Cip1 converts cancer cells from growth
arrest to undergoing apoptosis. Oncogene. 18:1131–1138.
62. Javelaud, D., and F. Besancon. 2002. Inactivation of
p21WAF1 sensitizes cells to apoptosis via an increase of both
p14ARF and p53 levels and an alteration of the Bax/Bcl-2
ratio. J. Biol. Chem. 277:37949–37954.
63. Botto, M., C. Dell’Agnola, A.E. Bygrave, E.M. Thompson,
H.T. Cook, F. Petry, M. Loos, P.P. Pandolfi, and M.J.
Walport. 1998. Homozygous C1q deficiency causes glomer-
ulonephritis associated with multiple apoptotic bodies. Nat.
Genet. 19:56–59.
64. Bickerstaff, M.C., M. Botto, W.L. Hutchinson, J. Herbert,
G.A. Tennent, A. Bybee, D.A. Mitchell, H.T. Cook, P.J.
Butler, M.J. Walport, and M.B. Pepys. 1999. Serum amyloid
P component controls chromatin degradation and prevents
antinuclear autoimmunity. Nat. Med. 5:694–697.
65. Wakeland, E.K., K. Liu, R.R. Graham, and T.W. Behrens.
2001. Delineating the genetic basis of systemic lupus erythe-
matosus. Immunity. 15:397–408.
66. Mitchell, D.A., M.C. Pickering, J. Warren, L. Fossati-
Jimack, J. Cortes-Hernandez, H.T. Cook, M. Botto, and
M.J. Walport. 2002. C1q deficiency and autoimmunity: the
effects of genetic background on disease expression. J. Immu-
nol. 168:2538–2543.
67. Balomenos, D., R. Rumold, and A.N. Theofilopoulos.
1997. The proliferative in vivo activities of lpr double-nega-
tive T cells and the primary role of p59fyn in their activation
and expansion. J. Immunol. 159:2265–2273.
68. Gmelig-Meyling, F., S. Dawisha, and A.D. Steinberg. 1992.
Assessment of in vivo frequency of mutated T cells in patients
with systemic lupus erythematosus. J. Exp. Med. 175:297–300.
69. Dayal, A.K., and G.M. Kammer. 1996. The T cell enigma in
lupus. Arthritis Rheum. 39:23–33.
70. Goronzy, J.J., and C.M. Weyand. 2001. Thymic function
and peripheral T-cell homeostasis in rheumatoid arthritis.
Trends Immunol. 22:251–255.
71. Petersen, L.D., G. Duinkerken, G.J. Bruining, R.A. van Lier,
R.R. de Vries, and B.O. Roep. 1996. Increased numbers of in
vivo activated T cells in patients with recent onset insulin-
dependent diabetes mellitus. J. Autoimmun. 9:731–737.
72. Smerdon, R.A., M. Peakman, M.J. Hussain, L. Alviggi, P.J.
Watkins, R.D. Leslie, and D. Vergani. 1993. Increase in si-
multaneous coexpression of naive and memory lymphocyte
markers at diagnosis of IDDM. Diabetes. 42:127–133.
73. Arbogast, A., S. Boutet, M.A. Phelouzat, O. Plastre, R.
Quadri, and J.J. Proust. 1999. Failure of T lymphocytes from
elderly humans to enter the cell cycle is associated with low
Cdk6 activity and impaired phosphorylation of Rb protein.
Cell. Immunol. 197:46–54.